Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.
Second quarter CAPLYTA total prescriptions (TRx) increased 22% versus the previous…
